Thiogenesis Therapeutics Corp.

Symbol: TSXV: TTI OTCPK: TTIPF
Market Cap: Private
Sector: Biotechnology
Summary:
  • Developing prodrugs that act as precursors to thiol-active compounds – with the potential to treat serious pediatric diseases.
  • Thiols have powerful antioxidant properties that may address oxidative stress in the mitochondria (“powerhouse of the cell”) – mitochondrial dysfunction and oxidative stress are at the core of many metabolic disorders.
  • In 2024, planning to initiate Phase 2 clinical trials in a mitochondrial disease, Rett syndrome and pediatric NASH.